Cita APA (7a ed.)

Mori, M., Hara, T., Kikuchi, M., Shimizu, H., Miyamoto, T., Iwashima, S., . . . Fuse, S. (2018). Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: A phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Nature Portfolio.

Cita Chicago Style (17a ed.)

Mori, Masaaki, et al. Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease: A Phase 3, Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Trial. Nature Portfolio, 2018.

Cita MLA (8a ed.)

Mori, Masaaki, et al. Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease: A Phase 3, Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Trial. Nature Portfolio, 2018.